Description
(161 genes Mutation, Copy Number
variations and Fusion analysis)
Tissue, NA, Fasting or Non Fasting: As suggested by doctor
Sample Required:
FFPE tissue block at room temperature OR fresh tissue in DCGL Preservative Solution at 2–8°C; tumour content should be >10%.
Test Time:
Sample collection varies by biopsy. Report typically available in 8–12 working days.
Test Normal Range:
No fixed normal range; results are interpretive molecular findings.
What is the Test?
This is a next-generation sequencing (NGS)–based tumour profiling panel that analyses **161 cancer-related genes**, covering **mutations, copy-number variations (CNVs), and gene fusion analysis**. It provides an extensive genomic overview to support cancer diagnosis and targeted therapy selection.
Test Procedure:
Tumour tissue undergoes DNA/RNA extraction followed by sequencing across the 161-gene panel to detect mutations, CNVs, and fusions.
When to Take the Test:
At cancer diagnosis, recurrence, or when broad molecular profiling is required for clinical decision-making.
Who Should Take This Test:
Patients with solid tumours where extended genomic analysis may influence targeted therapy or clinical trial eligibility.
Precautions for Exceptional Cases (Pregnancy, etc.):
Inform your clinician if pregnant or on anticoagulants; ensure tumour block contains >10% tumour.
